Genetic and exposure risks for chronic beryllium disease

Clinics in Chest Medicine

Volumn 23, Issue 4, 2002, Pages 827-839

  Maier, Lisa A ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM;

ANTIGEN SPECIFICITY; BERYLLIOSIS; CELL PROLIFERATION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GRANULOMATOUS INFLAMMATION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; LONG TERM EXPOSURE; NONLINEAR SYSTEM; PARTICLE SIZE; PHYSICAL CHEMISTRY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; SOLUBILITY;

BERYLLIOSIS; CHRONIC DISEASE; CLINICAL TRIALS; ENVIRONMENTAL EXPOSURE; HUMANS; RISK FACTORS;

EID: 0036956244     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00029-1     Document Type: Review

References (85)

1. Weber H, Engelhardt WE. Anwendung bei der Untersuchungen von Stauben aus der Berylliumgewinnung. Zentralbl Gewerbehyg Unfallverhuet [Procedures for the Examination of Dust Created During Beryllium Extraction. Journal of Industrial Hygiene and Accident Prevention] 1933;10:41.
2. Gelman I. Poisoning by vapors of beryllium oxyfluoride. J Industr Hyg Tox 1936;18:371-99.
3. Berkovits M, Izrael B. Changes in the lungs by beryllium oxyfluoride poisoning. Klin Med 1940;18:117-22.
4. Van Ordstrand HS, Hughes R, DeNardi JM, et al. Beryllium poisoning. JAMA 1945;129:1084-90.
5. Shilen J, Galloway A, Mellor J. Beryllium oxide from beryl - Health hazards incident to extraction. Ind Med 1944;13:464-9.
6. Cullen MR, Kominsky JR, Rossman MD, et al. Chronic beryllium disease in a precious metal refinery: Clinical, epidemiologic, and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am Rev Respir Dis 1987;135:201-8.
7. Kreiss K, Mroz MM, Zhen B, et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993;148:985-91.
8. Kreiss K, Wasserman S, Mroz MM, et al. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993;35:267-74.
9. Kreiss K, Mroz MM, Zhen B, et al. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997;54:605-12.
10. Newman LS, Mroz MM, Maier LA, et al. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001;43:231-7.
11. Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. Arch Industr Hyg Occup Med 1951;4:123-51.
12. Bama BP, Deodhar SD, Gautam S, et al. Experimental beryllium-induced lung disease: II. Analyses of bronchial lavage cells in strains 2 and 13 guinea pigs. Int Arch Allergy Appl Immunol 1984;73:49-55.
13. Barna BP, Deodhar SD, Chiang T, et al. Experimental beryllium-induced lung disease: I. Differences in immunologic response to beryllium compounds in strains 2 and 13 guinea pigs. Int Arch Allergy Appl Immunol 1984;73:42-8.
14. Richeldi L, Kreiss K, Mroz MM, et al. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997;32:337-40.
15. Richeldi L, Sorrentino R, Saltini C. HLA-DPβ1 glutamate 69: A genetic marker of beryllium disease. Science 1993;262:242-4.
16. McConnochie K, Williams WR, Kilpatrick GS, et al. Chronic beryllium disease in identical twins. Br J Dis Chest 1988;82:431-5.
17. Tarlo SM, Rhee K, Powell E, et al. Marked tachypnea in siblings with chronic beryllium disease due to copper-beryllium alloy. Chest 2001;119:647-50.
18. Maier LA, Lympany PA, McGrath DS, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. Am J Respir Crit Care Med 2001;163:A242.
19. 3. Am J Industr Med 1996;30:16-25.
20. Hardy HL. Beryllium poisoning: Lessons in control of man-made disease. N Engl J Med 1965;273:1188-99.
21. Eisenbud M, Wanta RC, Dustan C, et al. Non-occupational berylliosis. J Industr Hyg Toxicol 1949;31:281-94.
22. Eisenbud M, Lisson J. Epidemiological aspects of beryllium-induced non-malignant lung disease: A 30-year update. J Occup Med 1983;25:196-202.
23. Lieben J, Metzner F. Epidemiological findings associated with beryllium extraction. Am Industr Hyg Assoc J 1959;20:504-8.
24. Freiman DG, Hardy HL. Beryllium disease: The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. Beryllium Case Registry. Hum Pathol 1970;1:25-44.
25. Newman LS. Metals that cause sarcoidosis. Semin Respir Infect 1998;13:212-20.
26. Tepper LB, Hardy HL, Chamberlin RI. Toxicity of beryllium compounds. In: Browning E, editor. Elsevier monographs on toxic agents. Amsterdam: Elsevier Publishing Company; 1961. p. 1-190.
27. Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease: Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969;46:545-61.
28. Lieben J, Vought V. Quantitative beryllium studies in postmorten lungs. Arch Environ Health 1963;7:183-7.
29. Curtis GH. Cutaneous hypersensitivity due to beryllium: A study of thirteen cases. AMA Archs Dermatol Syph 1951;64:470-82.
30. Curtis GH. The diagnosis of beryllium disease with special reference to the patch test. AMA Arch Industr Health 1959;19:150-3.
31. Epstein PE, Dauber JH, Rossman MD, et al. Bronchoalveolar lavage in a patient with chronic berylliosis: Evidence for hypersensitivity pneumonitis. Ann Intern Med 1982;97:213-6.
32. Mroz MM, Kreiss K, Lezotte DC, et al. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991;88:54-60.
33. Rossman MD, Kern JA, Elias JA, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium: A test for chronic beryllium disease. Ann Intern Med 1988;108:687-93.
34. Kreiss K, Newman LS, Mroz MM, et al. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31:603-8.
35. Maier LA, Newman LS. Beryllium disease. In: Rom WN, editor. Environmental and occupational medicine. Philadelphia: Lippincott-Raven Publishers; 1998. p. 1017-31.
36. Newman LS, Kreiss K, King Jr TE, et al. Pathologic and immunologic alterations in early stages of beryllium disease. Am Rev Respir Dis 1989;139:1479-86.
37. Newman LS, Balkissoon R, Daniloff E, et al. Rate of progression from beryllium sensitization to chronic beryllium disease is 9-19% per year. Am J Respir Crit Care Med 1998;157:A145.
38. Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 1993;148:661-6.
39. Kreiss K, Cox-Ganser J. Metalworking fluid-associated hypersensitivity pneumonitis: A workshop summary. Am J Ind Med 1997;32:423-32.
40. Stange AW, Hilmas DE, Furman FJ, et al. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg 2001;16:405-17.
41. Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001;74:167-76.
42. Saltini C, Winestock K, Kirby M, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989;320:1103-9.
43. Fontenot AP, Kotzin BL, Comment CL, et al. Expansions of T cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease. Am J Respir Cell Mol Biol 1998;18:581-9.
44. Fontenot A, Falta M, Newman L, et al. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999;163:1019-26.
45. Fontenot AP, Maier LA, Canavera SJ, et al. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol 2002;168:3627-34.
46. Fontenot AP, Torres M, Marshall WH, et al. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000;97:12717-22.
47. Lombardi G, Germain C, Uren J, et al. HLA-DP allelespecific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol 2001;166:3549-55.
48. Wang Z, White P, Petrovic M, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999;163:1647-53.
49. Tinkle SS, Kittle LA, Schumacher BA, et al. Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 1997;158:518-26.
50. Tinkle SS, Newman LS. Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 1997;156:1884-91.
51. Bost TW, Riches DWH, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express mRNA for TNF-α and IL-6 but not IL-1β. Am J Respir Cell Mol Biol 1994;10:506-13.
52. Maier LA, Sawyer RT, Tinkle SS, et al. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 2001;17:403-15.
53. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
54. Bergeron A, Bonay M, Kambouchner M, et al. Cytokine patterns in tuberculosis and sarcoid granulomas. J Immunol 1997;159:3034-43.
55. Tinkle SS, Kittle LA, Newman LS. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. J Immunol 1999;163:2747-53.
56. Hamada H, Sawyer RT, Kittle LA, et al. Beryllium stimulation does not activate transcription factors in a mouse hybrid macrophage cell line. Toxicology 2000;143:249-61.
57. Sawyer RT, Kittle LA, Hamada H, et al. Beryllium-stimulated production of tumor necrosis factor-alpha by a mouse hybrid macrophage cell line. Toxicology 2000;143:235-47.
58. Lieben J, Williams RR. Respiratory diseases associated with beryllium refining and alloy fabrication: 1968 Follow-up. J Occup Med 1969;9:480-5.
59. Newman LS, Kreiss K. Non-occupational chronic beryllium disease masquerading as sarcoidosis: Identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992;145:1212-4.
60. Sussman VH, Lieben J, Cleland JG. An air pollution study of a community surrounding a beryllium plant. Am Industr Hyg Assoc J 1959;20:504-8.
61. Stonehouse A, Zenczak S. Properties, production processes, and applications. In: Rossman M, Preuss O, Powers M, editors. Beryllium biomedical and environmental aspects. Baltimore: Williams & Wilkins; 1991. p. 27-55.
62. Martyny J, Maier L, Newman LS. Beryllium related issues. In: Greenberg M, Hamilton R, Phillips S, editors. Occupational, Industrial and Environmental Toxicology. Philadelphia: Harcourt Health Sciences; in press.
63. Reeves AL. Toxicodynamics. In: Rossman MD, Preuss OP, Powers MB, editors. Beryllium: Biomedical and Environmental Aspects. Baltimore: Williams and Wilkins; 1991. p. 87-93.
64. Kriebel D, Brain JD, Sprince NL, et al. The pulmonary toxicity of beryllium. Am Rev Respir Dis 1988;137:464-73.
65. Hoover MD, Castorina BT, Finch GL, et al. Determination of the oxide layer thickness on beryllium metal particles. Am Ind Hyg Assoc J 1989;50:550-3.
66. Hall RH, Scott JK, Laskin S, et al. Acute toxicity of inhaled beryllium III. Observations correlating toxicity with the physico-chemical properties of beryllium oxide dust. Arch Ind Hyg Occ Med 1950;2:25-48.
67. Reeves AL, Preuss OP. Immunotoxicity of beryllium. In: Dean JH, Luster MI, Munson AE, et al, editors. Immunotoxicology and immunopharmacology. New York: Raven Press; 1985. p. 441-56.
68. Kelleher PC, Martyny JW, Mroz MM, et al. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001;43:238-49.
69. Viet SM, Torma-Krajewski J, Rogers J. Chronic beryllium disease and beryllium sensitization at Rocky Flats: A case-control study. Am Ind Hyg Assoc J 2000;61:244-54.
70. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis in workers exposed to beryllium compounds. J Industr Hyg Toxicol 1946;28:197-211.
71. Shima S. [Hygienic control of beryllium]. Rodo no Kagaku 1971;26:36-46 [in Japanese].
72. Kent MS, Robins TG, Madl AK. Is total mass or mass of alveolar-deposited airborne particles of beryllium a better predictor of the prevalence of disease? A preliminary study of a beryllium processing facility. Appl Occup Environ Hyg 2001;16:539-58.
73. Barnard AE, Torma-Krajewski J, Viet SM. Retrospective beryllium exposure assessment at the Rocky Flats Environmental Technology Site. Am Ind Hyg Assoc J 1996;57:804-8.
74. Martyny JW, Hoover MD, Mroz MM, et al. Aerosols generated during beryllium machining. J Occup Environ Med 2000;42:8-18.
75. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001;18:677-84.
76. Rossman MD, Stubbs J, Lee CW, et al. Human leukocyte antigen Class II amino acid epitopes: Susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002;165:788-94.
77. Wang Z, Farris GM, Newman LS, et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001;165:27-38.
78. Maier LA, Sawyer RT, Bauer PA, et al. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 2001;164:1192-9.
79. Stubbs J, Argyris E, Lee CW, Monos D, Rossmann MD, et al. Genetic markers in beryllium hypersensitivity. Chest 1996;109:45S.
80. McCawley MA, Kent MS, Berakis MT. Ultrafine beryllium number concentration as a possible metric for chronic beryllium disease risk. Appl Occup Environ Hyg 2001;16:631-8.
81. Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis 1992;146:39-42.
82. Maier LA, Barker EA, Raynolds MV, Newman LS, et al. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med 1999;159:1342-50.
83. Allen RD. Polymorphism of the human TNF-alpha promoter-random variation or functional diversity? Mol Immunol 1999;36:1017-27.
84. Grutters JC, Sato H, Pantelidis P, et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002;165:1119-24.
85. Maier L, Martyny J, Mroz M, et al. Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease. Chest 2002;121:81S-82S.